###begin article-title 0
###xml 36 41 <span type="species:ncbi:9606">human</span>
Non-DNA binding, dominant-negative, human PPARgamma mutations cause lipodystrophic insulin resistance
###end article-title 0
###begin p 1
These authors contributed equally to this work.
###end p 1
###begin title 2
Summary
###end title 2
###begin p 3
###xml 130 135 <span type="species:ncbi:9606">human</span>
PPARgamma is essential for adipogenesis and metabolic homeostasis. We describe mutations in the DNA and ligand binding domains of human PPARgamma in lipodystrophic, severe insulin resistance. These receptor mutants lack DNA binding and transcriptional activity but can translocate to the nucleus, interact with PPARgamma coactivators and inhibit coexpressed wild-type receptor. Expression of PPARgamma target genes is markedly attenuated in mutation-containing versus receptor haploinsufficent primary cells, indicating that such dominant-negative inhibition operates in vivo. Our observations suggest that these mutants restrict wild-type PPARgamma action via a non-DNA binding, transcriptional interference mechanism, which may involve sequestration of functionally limiting coactivators.
###end p 3
###begin title 4
Introduction
###end title 4
###begin p 5
###xml 179 201 171 193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R58">Tontonoz et al., 1994b</xref>
###xml 203 221 195 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R7">Barak et al., 1999</xref>
###xml 223 241 215 233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R44">Rosen et al., 1999</xref>
###xml 978 1000 942 964 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R32">Lehrke and Lazar, 2005</xref>
###xml 1002 1014 966 978 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R48">Savage, 2005</xref>
###xml 1122 1142 1082 1102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R31">Lehmann et al., 1995</xref>
###xml 1244 1269 1204 1229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R16">Desvergne and Wahli, 1999</xref>
###xml 1343 1363 1303 1323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R59">Tzameli et al., 2004</xref>
The nuclear receptor (NR) peroxisome proliferator-activated receptor gamma (PPARgamma) is a ligand-inducible transcription factor that is essential for adipocyte differentiation (Tontonoz et al., 1994b; Barak et al., 1999; Rosen et al., 1999). Alternative splicing and differential promoter usage generates two protein isoforms: PPARgamma2, expressed from a single gamma2 promoter, contains an additional 28 amino-terminal amino acids and is nearly adipose-specific; PPARgamma1, whose expression can be regulated by multiple (gamma1, gamma3, gamma4) promoters, is more ubiquitously distributed. In addition to adipogenesis, PPARgamma also plays an important role in adipocyte lipid metabolism, regulating target genes (lipoprotein lipase, fatty-acid transport protein, aquaporin) that mediate triglyceride hydrolysis and fatty acid and glycerol uptake, together with genes (acylCoA synthetase, PEPCK, glycerol kinase) involved in fatty acid re-esterification and lipid storage (Lehrke and Lazar, 2005; Savage, 2005). The thiazolidinedione (TZD) class of antidiabetic agents are synthetic, high-affinity PPARgamma ligands (Lehmann et al., 1995) and putative endogenous activators include fatty acids, eicosanoids, and prostaglandin derivatives (Desvergne and Wahli, 1999) as well as undefined ligands produced during adipocyte differentiation (Tzameli et al., 2004).
###end p 5
###begin p 6
###xml 274 296 266 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R6">Altshuler et al., 2000</xref>
###xml 567 587 551 571 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R9">Barroso et al., 1999</xref>
###xml 790 810 774 794 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R9">Barroso et al., 1999</xref>
###xml 812 833 796 817 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R3">Agostini et al., 2004</xref>
###xml 917 942 893 918 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R28">Kallenberger et al., 2003</xref>
###xml 1204 1224 1176 1196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R9">Barroso et al., 1999</xref>
###xml 1498 1517 1466 1485 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R24">Hegele et al., 2002</xref>
###xml 1519 1541 1487 1509 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R2">Agarwal and Garg, 2002</xref>
###xml 1543 1562 1511 1530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R50">Savage et al., 2003</xref>
The most common population genetic variant of PPARgamma is a polymorphism replacing alanine for proline at codon 12 (Pro12Ala) in PPARgamma2, with a meta-analysis of association studies showing that the Pro allele confers a modest but significant increase in diabetes risk (Altshuler et al., 2000). The discovery that PPARgamma is a target for TZDs, which act by enhancing tissue insulin sensitivity, prompted screening of a cohort of subjects with severe insulin resistance, with identification of two missense PPARgamma mutations (P467L, V290M) in unrelated cases (Barroso et al., 1999). Functional studies showed that these mutant receptors retain DNA binding but exhibit significant impairment of transcriptional activation and coactivator recruitment in response to different ligands (Barroso et al., 1999; Agostini et al., 2004), due to the mutations destabilizing the carboxyterminal alpha helix of PPARgamma (Kallenberger et al., 2003), which mediates these functions. Consonant with heterozygosity in affected subjects and dominant inheritance in one kindred, the P467L and V290M mutant receptors inhibited the transcriptional activity of wild-type (WT) PPARgamma in a dominant-negative manner (Barroso et al., 1999). Subsequently, two further heterozygous mutations in the ligand binding domain (LBD) of PPARgamma (R425C; F388L) have been described, with recognition that in addition to insulin resistance the phenotype also includes a stereotyped pattern of partial lipodystrophy (PLD) (Hegele et al., 2002; Agarwal and Garg, 2002; Savage et al., 2003).
###end p 6
###begin p 7
###xml 122 125 122 125 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">553</sup>
###xml 641 660 633 652 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R49">Savage et al., 2002</xref>
###xml 991 1012 979 1000 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R5">Al-Shali et al., 2004</xref>
###xml 734 739 <span type="species:ncbi:9606">human</span>
Following this, we described several individuals who were heterozygous for a frameshift/premature stop codon mutation, ([A553DeltaAAAiT]fs.185[stop186]-hereafter abbreviated to FSX) in the DNA binding domain (DBD) of PPARgamma, with this truncation mutant lacking DNA binding, transcriptional, and dominant-negative activity. Significantly, heterozygosity for the FSX mutation alone was not associated with insulin resistance, but individuals who were doubly heterozygous, with an additional defect in an unrelated gene encoding the muscle-specific regulatory subunit of protein phosphatase 1 (PPP1R3A), exhibited severe insulin resistance (Savage et al., 2002). Heterozygosity for a single nucleotide substitution in the promoter of human PPARgamma4 leading to its altered expression in vitro has been associated with PLD and insulin resistance in one family, but the authors did not exclude the possibility of interaction with a defect at a second genetic locus to produce this phenotype (Al-Shali et al., 2004).
###end p 7
###begin p 8
###xml 115 118 111 114 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">935</sup>
###xml 58 63 <span type="species:ncbi:9606">human</span>
Here, we describe the identification of five heterozygous human PPARgamma mutations (C114R, C131Y, C162W, R357X, [A935DeltaC]fs.312[stop315]-hereafter abbreviated to FS315X) not associated with a PPP1R3A gene defect, in unrelated cases of lipodystrophic insulin resistance and show that these mutants inhibit WT receptor action via a non-DNA binding, dominant-negative mechanism.
###end p 8
###begin title 9
Results and Discussion
###end title 9
###begin title 10
Heterozygous PPARgamma mutations are associated with lipodystrophic insulin resistance
###end title 10
###begin p 11
###xml 104 111 104 111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">Table 1</xref>
###xml 243 263 239 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R9">Barroso et al., 1999</xref>
###xml 265 284 261 280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R24">Hegele et al., 2002</xref>
###xml 286 308 282 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R2">Agarwal and Garg, 2002</xref>
###xml 310 329 306 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R50">Savage et al., 2003</xref>
###xml 386 393 382 389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">Table 1</xref>
The case histories (see the Supplemental Data available with this article online) and characterization (Table 1) of index subjects (S1-S5) harboring PPARgamma mutations indicate many of the features associated with previously described cases (Barroso et al., 1999; Hegele et al., 2002; Agarwal and Garg, 2002; Savage et al., 2003). All subjects showed marked fasting hyperinsulinaemia (Table 1) with acanthosis nigricans in a subset (S3, S4, S5), denoting severe insulin resistance; total body fat was reduced in all individuals, and imaging indicated a stereotyped pattern of partial lipodystrophy affecting gluteal (Figure S1) and peripheral limb depots; hepatic steatosis and marked dyslipidaemia (raised triglycerides, low high-density lipoprotein cholesterol [HDL-C]) with secondary complications (cutaneous eruptive xanthomata S3, S4; pancreatitis S5) were features of all cases; several individuals (S2, S3, S5) exhibited early-onset hypertension.
###end p 11
###begin p 12
###xml 71 76 67 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG</italic>
###xml 225 230 221 226 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG</italic>
###xml 355 375 351 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R9">Barroso et al., 1999</xref>
###xml 483 504 479 500 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R62">Williams et al., 1995</xref>
###xml 768 775 764 771 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPP1R3A</italic>
###xml 911 930 907 926 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R49">Savage et al., 2002</xref>
###xml 303 311 <span type="species:ncbi:9606">patients</span>
###xml 452 464 <span type="species:ncbi:9606">participants</span>
We sequenced the gamma4 promoter, coding exons and splice junctions of PPARG and identified heterozygous, missense mutations in the DBD (S1-S3), or premature stop mutations in the LBD (S4, S5) of the receptor in index cases. PPARG has also been sequenced by us in 215 additional subjects, comprising 93 patients from our severe insulin resistance cohort (Barroso et al., 1999), 48 CEPH individuals of European descent and 27 Europid, hyperinsulinaemic participants in the Ely study (Williams et al., 1995), and 47 controls from four different ethnic groups, or sequenced by others in 24 African and 23 CEPH European individuals (Seattle SNPs project, ), and other than the Pro12Ala polymorphism neither these or other mutations have been identified. We also sequenced PPP1R3A in each proband and identified no mutations or polymorphisms, excluding a second genetic defect at this locus as described previously (Savage et al., 2002).
###end p 12
###begin p 13
###xml 466 475 458 467 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1B</xref>
Heterozygosity for PPARgamma mutations in a parent and grandparent of S3 and a parent of S5 segregated with phenotype, constituting a dominant inheritance pattern in two families; one sibling of S2 with dyslipidaemia and insulin resistance was heterozygous for the PPARgamma mutation whereas another genetically unaffected sibling was biochemically normal; the ascertainable family members of S1 were unaffected and normal and no relatives of S4 could be contacted (Figure 1B).
###end p 13
###begin title 14
PPARgamma mutants fail to bind DNA and are transcriptionally inactive
###end title 14
###begin p 15
###xml 244 253 244 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1A</xref>
###xml 432 451 428 447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R49">Savage et al., 2002</xref>
Three missense mutations involve highly conserved cysteine residues within (C114R, C131Y, C162W) the DBD and two further nonsense (R357X) or frameshift/premature stop (FS315X) mutations truncate the receptor within the central part of its LBD (Figure 1A), predicting loss-of-function of the mutant proteins. We therefore characterised and compared the properties of these PPARgamma mutants with the FSX mutant described previously (Savage et al., 2002).
###end p 15
###begin p 16
###xml 140 161 136 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R3">Agostini et al., 2004</xref>
###xml 163 181 159 177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R64">Zamir et al., 1997</xref>
###xml 249 258 245 254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1C</xref>
###xml 478 487 474 483 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1A</xref>
###xml 490 508 486 504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R64">Zamir et al., 1997</xref>
###xml 510 525 506 521 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R63">Wu et al., 2003</xref>
The receptor mutants exhibited negligible transcriptional activity, lacking constitutive basal activity noted previously with WT PPARgamma (Agostini et al., 2004; Zamir et al., 1997) as well as any response to rosiglitazone, a TZD receptor agonist (Figure 1C). Such complete loss of function was similar to the FSX mutant and might be anticipated with analogous truncation mutants (FS315X, R357X) not possessing the transactivation (AF2) domain at the receptor carboxyterminus (Figure 1A) (Zamir et al., 1997; Wu et al., 2003), but the lack of function with DBD mutants (C114R, C131Y, C162W), prompted further investigation of their DNA binding properties.
###end p 16
###begin p 17
###xml 238 260 234 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R26">Ijpenberg et al., 1997</xref>
###xml 428 447 420 439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R55">Temple et al., 2005</xref>
###xml 680 689 672 681 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1D</xref>
###xml 905 923 893 911 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R17">Gampe et al., 2000</xref>
###xml 950 959 938 947 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1A</xref>
###xml 1218 1236 1206 1224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R17">Gampe et al., 2000</xref>
###xml 1382 1400 1370 1388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R30">Lazar et al., 1991</xref>
PPARgamma heterodimerizes with the retinoid X receptor (RXR) and this complex has been shown to bind a DNA response element (PPARE), consisting of a direct repeat (DR1) of the consensus sequence (AGGTCA) separated by a single nucleotide (Ijpenberg et al., 1997) and a recent study has suggested that the stringency of PPARgamma binding to some response elements is relatively relaxed, not needing complete integrity of its DBD (Temple et al., 2005). A range of previously documented or predicted PPAREs from known target genes were therefore tested in electrophoretic mobility shift assays and both DBD and LBD truncation receptor mutants showed negligible heterodimeric binding (Figure 1D). To examine interaction of mutant receptors with RXR, we coexpressed VP16-full length PPARgamma fusions with Gal4DBD-RXR in a mammalian two-hybrid assay. In keeping with preservation of the dimerization interface (Gampe et al., 2000) within their intact LBD (Figure 1A), the DBD mutants interacted readily whereas the FS315X, R357X, and FSX mutants lacking this interface failed to be recruited to Gal4-RXR (Figure S2). It was therefore conceivable that the DBD mutants could be recruited indirectly to a PPARE by binding RXR (Gampe et al., 2000), or conversely, that the LBD truncation mutants might bind a PPARE monomerically as has been documented with the thyroid hormone receptor (TR) (Lazar et al., 1991). However, unlike WT receptor, VP16-full length, mutant PPARgamma fusions were unable to activate a PPARE-containing reporter gene (Figure S3), indicating that like FSX, these PPARgamma mutants do not bind DNA directly or indirectly.
###end p 17
###begin title 18
PPARgamma mutants translocate to the nucleus and interact with cofactors
###end title 18
###begin p 19
###xml 73 93 69 89 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R4">Akiyama et al., 2002</xref>
###xml 246 255 242 251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1A</xref>
###xml 258 291 254 287 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R22">Guiochon-Mantel and Milgrom, 1993</xref>
###xml 293 309 289 305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R66">Zhu et al., 1998</xref>
###xml 592 601 584 593 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1E</xref>
The intracellular localization of WT PPARgamma is predominantly nuclear (Akiyama et al., 2002) and, analogous to steroid/thyroid hormone receptors, may be dependent on a putative nuclear localisation signal (NLS) located between its DBD and LBD (Figure 1A) (Guiochon-Mantel and Milgrom, 1993; Zhu et al., 1998). Studies of GFP-PPARgamma fusions showed that, in keeping with preservation of the putative NLS, both DBD and LBD truncation mutants localized to the nucleus comparably to WT, whereas the FSX truncation mutant, which lacks this sequence, remained cytoplasmic similar to GFP alone (Figure 1E).
###end p 19
###begin p 20
###xml 169 187 165 183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R37">Onate et al., 1995</xref>
###xml 401 417 389 405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R67">Zhu et al., 1996</xref>
###xml 419 423 407 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R68">1997</xref>
###xml 425 440 413 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R18">Ge et al., 2002</xref>
###xml 688 697 676 685 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1F</xref>
###xml 963 994 943 974 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R41">Puigserver and Spiegelman, 2003</xref>
###xml 1067 1090 1035 1058 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R40">Puigserver et al., 1999</xref>
###xml 1171 1190 1135 1154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R56">Tomaru et al., 2006</xref>
###xml 1249 1273 1209 1233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R53">Surapureddi et al., 2002</xref>
###xml 1440 1449 1400 1409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1G</xref>
We next examined whether the PPARgamma mutants might also retain the ability to interact with transcriptional coactivators. Steroid receptor coactivator-1 (SRC1/NCoA1) (Onate et al., 1995) and PPARgamma binding protein/thyroid receptor-associated protein 220 (PBP/TRAP220) interact directly with the AF2 domain of PPARgamma, with the latter cofactor being required for receptor-mediated adipogenesis (Zhu et al., 1996, 1997; Ge et al., 2002). Consistent with preservation of their AF2 domains, protein-protein interaction assays showed ligand-dependent binding of SRC1 or TRAP220 to the DBD mutants, but no specific interaction with FSX or LBD truncation mutants, which lack this region (Figure 1F). Conversely, we hypothesized that the PPARgamma LBD truncation mutants would retain the ability to recruit coactivators, which can interact with receptor independently of its AF2 domain. PPARgamma coactivator-1 (PGC1), which augments receptor action in fat cells (Puigserver and Spiegelman, 2003), can bind PPARgamma via its DBD and hinge region (alphaalpha 128-229) (Puigserver et al., 1999); PDIP, isolated in a two hybrid assay using the DBD/hinge region of PPARgamma (Tomaru et al., 2006), is a coactivator that also enhances PPARalpha activity (Surapureddi et al., 2002). Both PGC1 and PDIP bound WT or FS315X and R357X LBD truncation mutants in protein-protein interaction assays, whereas the FSX mutant showed negligible interaction (Figure 1G).
###end p 20
###begin title 21
PPARgamma signaling is reduced in mutation-containing primary cells ex vivo or mutant-expressing cells in vitro
###end title 21
###begin p 22
###xml 258 280 250 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R57">Tontonoz et al., 1994a</xref>
###xml 282 299 274 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R21">Guan et al., 2005</xref>
###xml 356 375 348 367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R39">Pelton et al., 1999</xref>
###xml 649 669 633 653 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R23">Gurnell et al., 2000</xref>
###xml 730 739 714 723 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2A</xref>
###xml 184 190 <span type="species:ncbi:10090">murine</span>
###xml 309 314 <span type="species:ncbi:9606">human</span>
###xml 527 532 <span type="species:ncbi:9606">human</span>
The observation that these PPARgamma mutants translocate to the nucleus and interact with coactivators raised the possibility that they might interfere with WT receptor signaling. The murine adipocyte P2 (aP2) gene is a classical target of PPARgamma action (Tontonoz et al., 1994a; Guan et al., 2005) and the human homolog (FABP4) is similarly responsive (Pelton et al., 1999). When coexpressed with WT PPARgamma at equivalent levels in 3T3-L1 adipocytes, the DBD and LBD mutants blocked WT receptor mediated activation of the human aP2/FABP4 gene promoter comparably to an artificial, dominant-negative PPARgamma mutant (AF2) described previously (Gurnell et al., 2000), whereas FSX lacked dominant-negative inhibitory activity (Figure 2A).
###end p 22
###begin p 23
###xml 362 383 354 375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R54">Szatmari et al., 2004</xref>
###xml 772 781 756 765 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2B</xref>
###xml 1175 1184 1151 1160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2C</xref>
###xml 1479 1488 1447 1456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2D</xref>
###xml 1571 1587 1539 1555 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R14">Culbertson, 1999</xref>
###xml 1673 1682 1637 1646 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2E</xref>
###xml 222 227 <span type="species:ncbi:9606">human</span>
We wished to determine whether such divergent dominant-negative inhibition by these PPARgamma mutants versus FSX might operate in vivo. PPARgamma is highly expressed in immature dendritic cells (IDCs) derived from primary human blood monocytes and mediates marked receptor responsiveness, with strong ligand-dependent induction of aP2 expression in these cells (Szatmari et al., 2004). Induction of aP2/FABP4 expression in IDCs containing DBD or LBD PPARgamma mutations was severely attenuated compared to responses in control cells from either normal individuals (WT) or from subjects (IR) with comparable insulin resistance without a PPARgamma gene defect. Significantly, aP2 induction in FSX mutation-containing cells was comparable to responses from control subjects (Figure 2B). We examined other PPARgamma target genes, identified from extensive microarray profiling of normal IDCs (I.S. and L.N., unpublished data) and found that responses to PPARgamma agonist in DBD and LBD truncation mutation-containing cells were markedly attenuated whereas FSX mutation-containing cells exhibited responses that were either similar or only slightly reduced compared to WT cells (Figure 2C). PPARgamma mRNA levels in control and mutation-containing primary cells were similar (data not shown), suggesting that differential responsiveness was not due to altered receptor expression. Furthermore, PPARgamma mRNA from both WT and R357X alleles was expressed in mutation-containing IDCs (Figure 2D), indicating that the R357X transcript is not subject to nonsense-mediated decay (Culbertson, 1999) and both WT and R357X mutant PPARgamma proteins were also expressed in these cells (Figure 2E).
###end p 23
###begin p 24
###xml 279 288 271 280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3A</xref>
###xml 315 324 307 316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3B</xref>
###xml 222 227 <span type="species:ncbi:9606">human</span>
Finally, we determined whether dominant-negative inhibition by a non-DNA binding PPARgamma mutant could interfere with a receptor-mediated biological process. Compared to control, WT PPARgamma or GFP adenovirus-transduced human preadipocyte cells, both cellular differentiation (Figure 3A) and aP2 gene expression (Figure 3B) in cells transduced with C114R mutant PPARgamma adenovirus were significantly reduced.
###end p 24
###begin title 25
Transcriptional interference via a non-DNA binding mechanism
###end title 25
###begin p 26
###xml 363 380 352 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R33">Love et al., 2000</xref>
###xml 716 734 701 719 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R36">Meyer et al., 1989</xref>
###xml 860 878 845 863 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R37">Onate et al., 1995</xref>
###xml 956 978 941 963 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R8">Barettino et al., 1994</xref>
###xml 1015 1033 1000 1018 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R65">Zhang et al., 1996</xref>
###xml 1588 1605 1565 1582 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R38">Park et al., 2003</xref>
###xml 1644 1661 1621 1638 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R61">Wada et al., 2006</xref>
###xml 1860 1881 1821 1842 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R45">Sabatino et al., 2005</xref>
###xml 2015 2035 1964 1984 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R19">Gervois et al., 1999</xref>
###xml 2232 2251 2181 2200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R34">Malloy et al., 1999</xref>
###xml 2349 2371 2295 2317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R52">Shibusawa et al., 2003</xref>
###xml 2493 2515 2439 2461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R32">Lehrke and Lazar, 2005</xref>
###xml 2882 2903 2820 2841 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R42">Reginato et al., 1998</xref>
###xml 2905 2924 2843 2862 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R43">Rocchi et al., 2001</xref>
###xml 2926 2945 2864 2883 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R11">Berger et al., 2003</xref>
###xml 1696 1701 <span type="species:ncbi:9606">human</span>
###xml 1984 1989 <span type="species:ncbi:9606">human</span>
###xml 2290 2296 <span type="species:ncbi:10090">murine</span>
We have shown previously that dominant-negative inhibition by PPARgamma mutants (P467L, V290M), is mediated by repression of target genes by DNA-bound mutant receptors, analogous to mechanisms of other mutant nuclear receptors (e.g., the v-erbA oncogene, TRbeta mutants in Resistance to Thyroid Hormone, PZLF-RARalpha fusion proteins in promyelocytic leukaemia) (Love et al., 2000). In contrast, the missense DBD and LBD truncation mutants identified here are unable to bind DNA, yet can inhibit WT PPARgamma action, suggesting a different mechanism of transcriptional interference. Competition for shared cofactors by NRs was postulated to explain mutual antagonism of progesterone and estrogen receptor signaling (Meyer et al., 1989) and the subsequent observation that SRC1, a shared coactivator, could relieve such "squelching", validated this hypothesis (Onate et al., 1995). Ligand-activated NRs have been shown to inhibit either their own function (Barettino et al., 1994) or that of heterologous receptors (Zhang et al., 1996) by limiting the availability of coactivators that are recruited to their transactivation domains. Our observations indicate that non-DNA binding, dominant-negative PPARgamma mutants can recruit coactivators, suggesting an analogous cofactor sequestration mechanism for thereby restricting WT receptor function. Evidence suggests that similar mechanisms operate to inhibit PPAR signaling in other contexts: analogous to our natural DBD mutants, others have generated artificial, dominant-negative, PPARgamma DBD mutants, which block either adipogenesis (Park et al., 2003) or neural stem cell differentiation (Wada et al., 2006); gammaORF4 is a newly identified human PPARgamma splice variant with a truncated LBD (alphaalpha273), which has dominant-negative activity and is selectively overexpressed in colorectal neoplasia (Sabatino et al., 2005); a dominant-negative PPARalpha splice variant with a truncated LBD (alphaalpha 174), is expressed in human tissues including liver (Gervois et al., 1999). Interestingly, heterozygous, non-DNA binding mutations in some nuclear receptors do not mediate a phenotype: mutations in the DBD of VDR only cause vitamin D resistance in the homozygous state (Malloy et al., 1999); a "knock-in" mutation in the DBD of murine TRbeta does not produce thyroid hormone resistance (Shibusawa et al., 2003). Possibly due to its pivotal role in regulating transcription of genes mediating both adipocyte formation and function (Lehrke and Lazar, 2005), we suggest that PPARgamma signaling may be particularly sensitive to interference via the postulated "squelching" mechanism, with deleterious metabolic consequences. A corollary of this may be that even modest enhancement of normal receptor activity in key tissues could be beneficial, supporting attempts to develop partial or tissue-specific PPARgamma agonists (Reginato et al., 1998; Rocchi et al., 2001; Berger et al., 2003).
###end p 26
###begin title 27
Experimental procedures
###end title 27
###begin title 28
Sequencing of PPARgamma and PPP1R3A genes
###end title 28
###begin p 29
###xml 194 213 186 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R49">Savage et al., 2002</xref>
The PPP1R3A (exons 1-4) and PPARgamma (exons 1-6, B and promoter region of PPARgamma4) genes were amplified using specific primers (available upon request) and sequenced as decribed previously (Savage et al., 2002).
###end p 29
###begin title 30
Construction of PPARgamma mutants and other vectors
###end title 30
###begin p 31
###xml 140 166 136 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R46">Sadowski and Ptashne, 1989</xref>
Full length WT and mutant PPARgamma1 cDNAs were cloned in pGEX4T (Amersham Pharmacia Biotech), pCMX-VP16 (kind gift from R. Evans), pSG424 (Sadowski and Ptashne, 1989) and pEGFP-C1 (Clontech), to yield GST-PPARgamma1, VP16-PPARgamma1, Gal4DBD-PPARgamma and GFP-PPARgamma1 fusions respectively.
###end p 31
###begin title 32
Electrophoretic mobility shift assays
###end title 32
###begin p 33
###xml 74 98 74 98 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R13">Collingwood et al., 1994</xref>
###xml 197 216 197 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R20">Graves et al., 1992</xref>
###xml 232 250 232 250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R27">Iwaki et al., 2003</xref>
###xml 261 282 261 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R25">Helledie et al., 2002</xref>
###xml 293 313 293 313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R35">Mascaro et al., 1998</xref>
###xml 323 344 323 344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R29">Laffitte et al., 2001</xref>
###xml 354 374 354 374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R10">Baumann et al., 2000</xref>
###xml 383 406 383 406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R51">Schoonjans et al., 1996</xref>
###xml 418 439 418 439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R60">Varanasi et al., 1996</xref>
###xml 450 468 450 468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R64">Zamir et al., 1997</xref>
###xml 160 165 <span type="species:ncbi:9606">human</span>
###xml 170 176 <span type="species:ncbi:10090">murine</span>
Electrophoretic mobility shift assays (EMSA) were performed as described (Collingwood et al., 1994) with different natural PPAREs: aP2, derived by alignment of human and murine promoter sequences (Graves et al., 1992); Adiponectin (Iwaki et al., 2003): ACoABP (Helledie et al., 2002); mCPT1, (Mascaro et al., 1998); LXRa, (Laffitte et al., 2001); CAP1, (Baumann et al., 2000); LPL, (Schoonjans et al., 1996); ACoAOx, (Varanasi et al., 1996); ACoAOx (Zamir et al., 1997).
###end p 33
###begin title 34
Transfection assays
###end title 34
###begin p 35
###xml 221 245 218 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R13">Collingwood et al., 1994</xref>
293EBNA cells, cultured in DMEM/10%FCS were transfected with Lipofectamine2000- or calcium phosphate-mediated in 96- or 24-well plates respectively and assayed for luciferase and beta-galactosidase activity as described (Collingwood et al., 1994) following 36 hr with or without ligand. 3T3-L1 adipocyte cells were cultured and transfected with Lipofectamine2000 in 24-well plates as described above.
###end p 35
###begin title 36
Cellular localisation of EGFP-tagged mutants
###end title 36
###begin p 37
293EBNA cells, grown on glass well slides were transfected using Lipofectamine 2000 with 1microg of EGFP-PPARgamma1 fusions, fixed with 4% paraformaldehyde, mounted using vectashield and fluorescence was visualized by digital microscopy.
###end p 37
###begin title 38
Peripheral blood monocyte purification and IDC culture
###end title 38
###begin p 39
###xml 260 261 260 261 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 407 438 407 438 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R47">Sallusto and Lanzavecchia, 1994</xref>
With ethical approval, monocytes were harvested from peripheral blood by Ficoll gradient centrifugation and immunomagnetic cell separation using anti-CD14-conjugated microbeads (VarioMACS; Miltenyi Biotec), resuspended in 6-well plates at a density of 1.5 x 106 cells/ml and cultured in RPMI 1640 plus 10% FBS containing 800U/ml GM-CSF (Leucomax) and 500U/ml IL-4 (Peprotech) to generate IDCs as described (Sallusto and Lanzavecchia, 1994) with or without exposure to ligand for 24 hr.
###end p 39
###begin title 40
Quantitative real-time PCR analysis of gene expression
###end title 40
###begin p 41
###xml 161 182 161 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R54">Szatmari et al., 2004</xref>
100ng of total RNA from IDCs, isolated using TRIZOL (Invitrogen), was reverse transcribed and analyzed by Taqman quantitative real-time PCR (qPCR) as described (Szatmari et al., 2004). The sequences of primers and probes are available upon request.
###end p 41
###begin p 42
Taqman qPCR low density arrays (TLDA) were used to quantify the expression of multiple target genes in IDCs, according to the manufacturer's instructions.
###end p 42
###begin p 43
To obtain cDNA, RNA was reverse transcribed using a High Capacity cDNA Archive kit (Applied Biosystems). The following commercially available Taqman assays (Applied Biosystems) were used: ADRP/ADFP (Hs00605340_m1), APOC1 (Hs00155790_m1), CLDN1 (Hs00221623_m1), aP2/FABP4 (Hs00609791_m1), CLECSF5 (Hs00183780_m1), CD1E (Hs00229421_m1), MYO1B (Hs00362654_m1), IL1R2 (Hs00174759_m1), OAS1 (Hs00242943_m1), p30 (Hs00396457_m1), cyclophilinA/PPIA (Hs99999904_m1). The comparative Ct method was used to quantify transcripts and normalize to cyclophilinA expression levels, which did not vary with ligand treatment. Thereafter, data were further normalized to expression levels in ligand-treated WT IDC samples using GeneSpring 7.2 software (Agilent).
###end p 43
###begin title 44
RFLP analysis of PPARgamma transcripts
###end title 44
###begin p 45
PPARgamma cDNAs were amplified from WT or R357X mutation-containing IDCs by RT-PCR using forward (CTCCTTGATGAATAAAGATGGGG) and reverse (ATGTCTTCAATGGGCTTCACAT) primers, the PCR products were digested with Cac8I enzyme (New England Biolabs) and analyzed by agarose gel electrophoresis.
###end p 45
###begin title 46
Immunoprecipitation and Western blot analysis
###end title 46
###begin p 47
###xml 172 177 <span type="species:ncbi:10090">mouse</span>
###xml 308 314 <span type="species:ncbi:9986">rabbit</span>
IDCs, harvested from 200ml of peripheral blood, were lysed in RIPA buffer containing a protease inhibitor cocktail (Roche) and cell supernatants immunoprecipitated using a mouse monoclonal anti-PPARgamma antibody (K8713, Perseus Proteomics) and analyzed by SDS-PAGE. Western blotting was carried out using a rabbit polyclonal anti-PPARgamma antibody (H-100, Santa Cruz Biotechnology).
###end p 47
###begin title 48
Adenovirus construction and expression
###end title 48
###begin p 49
###xml 129 149 125 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AdEasy Vector System</italic>
###xml 224 244 220 240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R23">Gurnell et al., 2000</xref>
###xml 333 334 329 330 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">7</sup>
###xml 449 470 445 466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R15">Darimont et al., 2003</xref>
###xml 677 695 673 691 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R1">Adams et al., 1997</xref>
###xml 264 268 <span type="species:ncbi:8284">Chub</span>
###xml 272 277 <span type="species:ncbi:9606">human</span>
Recombinant type 5 adenoviruses (Ad5) expressing GFP alone or with either WT or C114R mutant PPARgamma1 were generated using the AdEasy Vector System (Quantum Biotechnologies, Montreal), amplified and purified as described (Gurnell et al., 2000). 6-well plates of Chub-S7 human preadipocyte cells were cultured and infected with 2x107 pfu/well of recombinant virus 24 hr prior to differentiation in the presence of 100nM rosiglitazone as described (Darimont et al., 2003). Comparable infection efficiency was verified by fluorescence microscopy with subsequent qPCR analysis on days 0, 3, 5 and 7. Fully differentiated cells were fixed and stained with Oil Red-O as described (Adams et al., 1997).
###end p 49
###begin title 50
Supplementary Material
###end title 50
###begin title 51
Acknowledgments
###end title 51
###begin p 52
We would like to thank the Imaging Department (Royal Orthopaedic Hospital, Stanmore) for supplying control MRI data and Teturou Satoh (Gunma University) for providing PDIP1alpha ahead of publication. This work was supported by the Wellcome Trust (V.K.K.C., S.O.R., L.N., I.B., D.B.S.) and the Medical Research Council (N.J.W., J.W.R.S.).
###end p 52
###begin title 53
References
###end title 53
###begin article-title 54
Transcriptional activation by peroxisome proliferator-activated receptor gamma is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site
###end article-title 54
###begin article-title 55
###xml 92 99 <span type="species:ncbi:9606">patient</span>
A novel heterozygous mutation in peroxisome proliferator-activated receptor-gamma gene in a patient with familial partial lipodystrophy
###end article-title 55
###begin article-title 56
###xml 95 100 <span type="species:ncbi:9606">human</span>
Tyrosine agonists reverse the molecular defects associated with dominant-negative mutations in human peroxisome proliferator-activated receptor gamma
###end article-title 56
###begin article-title 57
Selective intranuclear redistribution of PPAR isoforms by RXR alpha
###end article-title 57
###begin article-title 58
A single-base mutation in the peroxisome proliferator-activated receptor gamma4 promoter associated with altered in vitro expression and partial lipodystrophy
###end article-title 58
###begin article-title 59
The common PPARgammaamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes
###end article-title 59
###begin article-title 60
PPARgamma is required for placental, cardiac and adipose tissue development
###end article-title 60
###begin article-title 61
Characterization of the ligand-dependent transactivation domain of thyroid hormone receptor
###end article-title 61
###begin article-title 62
###xml 31 36 <span type="species:ncbi:9606">human</span>
Dominant negative mutations in human PPARgamma are associated with severe insulin resistance, diabetes mellitus and hypertension
###end article-title 62
###begin article-title 63
Cloning and characterization of a functional peroxisome proliferator activator receptor-gamma-responsive element in the promoter of the CAP gene
###end article-title 63
###begin article-title 64
Distinct properties and advantages of a novel peroxisome proliferator-activated protein [gamma] selective modulator
###end article-title 64
###begin article-title 65
Obesity: Areport of the College of Physicians
###end article-title 65
###begin article-title 66
Spectrum of transcriptional dimerization and dominant negative properties of twenty different mutant thyroid hormone beta receptors in thyroid hormone resistance syndrome
###end article-title 66
###begin article-title 67
RNA surveillance. Unforeseen consequences for gene expression, inherited genetic disorders and cancer
###end article-title 67
###begin article-title 68
###xml 76 81 <span type="species:ncbi:9606">human</span>
Reconstitution of telomerase activity combined with HPV-E7 expression allow human preadipocytes to preserve their differentiation capacity after immortalization
###end article-title 68
###begin article-title 69
Peroxisome proliferator-activated receptors: nuclear control of metabolism
###end article-title 69
###begin article-title 70
Asymmetry in the PPARgamma/RXRalpha crystal structure reveals the molecular basis of heterodimerization among nuclear receptors
###end article-title 70
###begin article-title 71
Transcription coactivator TRAP220 is required for PPAR gamma 2-stimulated adipogenesis
###end article-title 71
###begin article-title 72
###xml 12 17 <span type="species:ncbi:9606">human</span>
A truncated human peroxisome proliferator-activated receptor alpha splice variant with dominant negative activity
###end article-title 72
###begin article-title 73
Identification of a fat cell enhancer: analysis of requirements for adipose tissue-specific gene expression
###end article-title 73
###begin article-title 74
Corepressors selectively control the transcriptional activity of PPARgamma in adipocytes
###end article-title 74
###begin article-title 75
Cytoplasmic-nuclear trafficking of steroid hormone receptors
###end article-title 75
###begin article-title 76
A dominant negative Peroxisome Proliferator-activated Receptor gamma (PPARgamma) mutant is a constitutive repressor and inhibits PPARgamma-mediated adipogenesis
###end article-title 76
###begin article-title 77
PPARG F388L, a transactivation-deficient mutant, in familial partial lipodystrophy
###end article-title 77
###begin article-title 78
###xml 180 186 <span type="species:ncbi:9606">humans</span>
The gene encoding the Acyl-CoA-binding protein is activated by peroxisome proliferator-activated receptor gamma through an intronic response element functionally conserved between humans and rodents
###end article-title 78
###begin article-title 79
Polarity and specific sequence requirements of peroxisome proliferator-activated receptor (PPAR)/retinoid X receptor heterodimer binding to DNA. A functional analysis of the malic enzyme gene PPAR response element
###end article-title 79
###begin article-title 80
Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors
###end article-title 80
###begin article-title 81
###xml 77 82 <span type="species:ncbi:9606">human</span>
A dynamic mechanism of nuclear receptor activation and its perturbation in a human disease
###end article-title 81
###begin article-title 82
###xml 22 27 <span type="species:ncbi:9606">human</span>
Autoregulation of the human liver X receptor alpha promoter
###end article-title 82
###begin article-title 83
Differential DNA binding by monomeric, homodimeric, and potentially heteromeric forms of the thyroid hormone receptor
###end article-title 83
###begin article-title 84
An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPARgamma)
###end article-title 84
###begin article-title 85
The many faces of PPARgamma
###end article-title 85
###begin article-title 86
Transcriptional repression by nuclear receptors: mechanisms and role in disease
###end article-title 86
###begin article-title 87
The vitamin D receptor and the syndrome of hereditary 1,25-dihydroxyvitamin D-resistant rickets
###end article-title 87
###begin article-title 88
###xml 11 16 <span type="species:ncbi:9606">human</span>
Control of human muscle-type carnitine palmitoyltransferase I gene transcription by peroxisome proliferator-activated receptor
###end article-title 88
###begin article-title 89
Steroid hormone receptors compete for factors that mediate their enhancer function
###end article-title 89
###begin article-title 90
Sequence and characterization of a coactivator for the steroid hormone receptor superfamily
###end article-title 90
###begin article-title 91
A dominant negative PPARgamma mutant shows altered cofactor recruitment and inhibits adipogenesis in 3T3-L1 cells
###end article-title 91
###begin article-title 92
###xml 96 101 <span type="species:ncbi:9606">human</span>
PPARgamma activation induces the expression of the adipocyte fatty acid binding protein gene in human monocytes
###end article-title 92
###begin article-title 93
Activation of PPARgamma coactivator-1 through transcription factor docking
###end article-title 93
###begin article-title 94
Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic regulator
###end article-title 94
###begin article-title 95
A potent antidiabetic thiazolidinedione with unique peroxisome proliferator-activated receptor gamma-activating properties
###end article-title 95
###begin article-title 96
A unique PPAR-gamma ligand with potent insulin-sensitizing yet weak adipogenic activity
###end article-title 96
###begin article-title 97
PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro
###end article-title 97
###begin article-title 98
A novel peroxisome proliferator-activated receptor gamma isoform with dominant negative activity generated by alternative splicing
###end article-title 98
###begin article-title 99
A vector for expressing GAL4(1-147) fusions in mammalian cells
###end article-title 99
###begin article-title 100
###xml 54 59 <span type="species:ncbi:9606">human</span>
Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha
###end article-title 100
###begin article-title 101
PPARgamma as a metabolic regulator: insights from genomics and pharmacology
###end article-title 101
###begin article-title 102
###xml 54 59 <span type="species:ncbi:9606">human</span>
Digenic inheritance of severe insulin resistance in a human pedigree
###end article-title 102
###begin article-title 103
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma
###end article-title 103
###begin article-title 104
Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression
###end article-title 104
###begin article-title 105
Thyroid hormone action in the absence of thyroid hormone receptor DNA-binding in vivo
###end article-title 105
###begin article-title 106
###xml 127 130 <span type="species:ncbi:10116">rat</span>
Identification of a transcriptionally active peroxisome proliferator-activated receptor alpha -interacting cofactor complex in rat liver and characterization of PRIC285 as a coactivator
###end article-title 106
###begin article-title 107
Activation of PPARgamma specifies a dendritic cell subtype capable of enhanced induction of iNKT cell expansion
###end article-title 107
###begin article-title 108
An intact DNA-binding domain is not required for peroxisome proliferator-activated receptor gamma (PPARgamma) binding and activation on some PPAR response elements
###end article-title 108
###begin article-title 109
Isolation and characterization of a transcriptional cofactor and its novel isoform that bind the deoxyribonucleic acid-binding domain of peroxisome proliferator-activated receptor-gamma
###end article-title 109
###begin article-title 110
mPPARgamma2: tissue-specific regulator of an adipocyte enhancer
###end article-title 110
###begin article-title 111
Stimulation of adipogenesis in fibroblasts by PPARgamma2, a lipid-activated transcription factor
###end article-title 111
###begin article-title 112
Regulated production of a peroxisome proliferator-activated receptor-gamma ligand during an early phase of adipocyte differentiation in 3T3-L1 adipocytes
###end article-title 112
###begin article-title 113
###xml 79 84 <span type="species:ncbi:9606">human</span>
Identification of a peroxisome proliferator-responsive element upstream of the human peroxisomal fatty acyl coenzyme A oxidase gene
###end article-title 113
###begin article-title 114
Peroxisome proliferator-activated receptor gamma -mediated regulation of neural stem cell proliferation and differentiation
###end article-title 114
###begin article-title 115
Undiagnosed gluocse intolerance in the community: The Isle of Ely Diabetes Project
###end article-title 115
###begin article-title 116
Ligand and coactivator identity determines the requirement of the charge clamp for coactivation of the peroxisome proliferator-activated receptor gamma
###end article-title 116
###begin article-title 117
Stoichiometric and steric principles governing repression by nuclear hormone receptors
###end article-title 117
###begin article-title 118
Ligand-dependent cross-talk between steroid and thyroid hormone receptors. Evidence for common transcriptional coactivator(s)
###end article-title 118
###begin article-title 119
Hormone-induced translocation of thyroid hormone receptors in living cells visualized using a receptor green fluorescent protein chimera
###end article-title 119
###begin article-title 120
###xml 30 35 <span type="species:ncbi:10090">mouse</span>
Cloning and identification of mouse steroid receptor coactivator-1 (mSRC-1), as a coactivator of peroxisome proliferator-activated receptor gamma
###end article-title 120
###begin article-title 121
Isolation and characterization of PBP, a protein that interacts with peroxisome proliferator-activated receptor
###end article-title 121
###begin title 122
Figures and Table
###end title 122
###begin p 123
###xml 69 74 <span type="species:ncbi:9606">human</span>
Identification and characterization of loss-of-function mutations in human PPARgamma
###end p 123
###begin p 124
###xml 0 2 0 2 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A)</bold>
A) Schematic representation of the three major domains of PPARgamma, showing the locations of the five mutations (C114R, C131Y, C162W, FS315X, and R357X-PPARgamma1 nomenclature) and the previously reported FSX mutation. NLS, nuclear localisation signal; RXR ID, retinoid X receptor interaction domain; AF2, activation function 2 domain.
###end p 124
###begin p 125
###xml 0 2 0 2 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B)</bold>
B) Family pedigrees showing genotypes (N, wild-type allele; M, mutant allele; NA, not available) and phenotypes (colored segments denote the presence of specific traits: green, type 2 diabetes mellitus/impaired glucose tolerance/hyperinsulinaemia; yellow, hypertriglyceridaemia; blue, hypertension; red, ischemic heart disease). Squares and circles represent male and female family members; slashed symbols denote deceased family members and arrows denote probands.
###end p 125
###begin p 126
###xml 0 2 0 2 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C)</bold>
###xml 216 217 212 213 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
C) PPARgamma mutants are unable to mediate ligand-dependent transactivation. 293EBNA cells were transfected with 100 ng of wild-type (WT), mutant, or empty (pcDNA3) expression vectors, together with 500 ng of (PPARE)3TKLUC reporter construct and 100 ng of Bos-beta-gal internal control plasmid, and increasing concentrations of rosiglitazone. Results are expressed as a percentage of the maximum activation with WT PPARgamma1 and represent the mean +/- SEM of at least three independent experiments in triplicate.
###end p 126
###begin p 127
###xml 0 2 0 2 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D)</bold>
###xml 495 500 <span type="species:ncbi:9606">human</span>
###xml 505 510 <span type="species:ncbi:10090">mouse</span>
###xml 515 518 <span type="species:ncbi:10116">rat</span>
D) PPARgamma mutants are unable to bind to DNA. EMSA with in vitro translated wild-type (WT) or mutant PPARgamma1 (C114R, C131Y, C162W, FS315X, R357X, or FSX) and RXR proteins coincubated with oligonucleotide duplexes corresponding to various natural PPAREs. aP2, adipocyte protein 2; ACoABP, acyl coenzyme A binding protein; mCPT1, muscle carnitine palmitoyl transferase 1; LXRalpha, liver X receptor a; CAP, cbl-associated protein; LPL, lipoprotein lipase, ACoAOx, acyl coenzyme A oxidase; h, human; m, mouse; r, rat; RL, reticulocyte lysate.
###end p 127
###begin p 128
###xml 0 2 0 2 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E)</bold>
E) The C114R, C131Y, C162W, FS315X, and R357X mutants translocate to the nucleus whereas the FSX mutant remains cytoplasmic. 293EBNA cells were transfected as described. Top panels show DAPI-staining (blue) of nuclei, middle panels the cellular localisation of GFP-tagged receptors, and lower panels merged images.
###end p 128
###begin p 129
###xml 0 2 0 2 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F)</bold>
###xml 213 215 205 207 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">35</sup>
###xml 412 414 404 406 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G)</bold>
###xml 621 623 601 603 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">35</sup>
###xml 653 658 <span type="species:ncbi:9606">human</span>
###xml 673 678 <span type="species:ncbi:9606">human</span>
F) The DBD PPARgamma mutants recruit SRC1 and TRAP220 coactivators, whereas the FS315X, R357X, and FSX truncation mutants do not interact. GST alone or WT and mutant GST-PPARgamma fusion proteins were tested with 35S-labeled in vitro translated SRC1 (upper panel) or TRAP220 (lower panel) in the absence or presence of rosiglitazone. Coomassie-stained gels confirmed comparable protein loading (data not shown). G) The LBD truncation mutants (FS315X, R357X) recruit PGC1alpha and PDIP1alpha coactivators, whereas the FSX mutant fails to interact. GST alone or WT and mutant GST-PPARgamma fusion proteins were tested with 35S-labeled in vitro translated human PGC1alpha and human PDIP1alpha in the absence of ligand. Coomassie-stained gels confirmed comparable protein loading (data not shown).
###end p 129
###begin p 130
PPARgamma mutants exhibit dominant-negative activity
###end p 130
###begin p 131
###xml 0 2 0 2 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A)</bold>
###xml 422 427 <span type="species:ncbi:9606">human</span>
A) The C114R, C131Y, C162W, FS315X, and R357X PPARgamma mutants inhibit transactivation by wild-type (WT) receptor, comparably to AF2, an artificial PPARgamma mutant described previously, whereas the FSX mutant lacks dominant-negative activity (upper panel). 3T3-L1 cells were cotransfected with 33 ng of WT receptor plus an equal amount of either empty (pcDNA3) or WT or mutant expression vector, together with 265 ng of human aP2LUC reporter plasmid and 65 ng of the internal control plasmid Bos-beta-gal. The dotted and dashed lines denote transcriptional activity of WT receptor in the absence and presence of ligand respectively. Results are expessed as fold induction relative to empty vector (pcDNA3 + pcDNA3) and represent the mean +/- SEM of at least three independent experiments in triplicate. Expression of wild-type and mutant receptor proteins was confirmed by Western blotting (lower panel) and the positions of WT, C114R, C131Y, C162W, and AF2 PPARgamma (open arrow) and FSX, FS315X and R357X truncation mutants (solid arrows) are indicated.
###end p 131
###begin p 132
###xml 0 8 0 8 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B and C)</bold>
###xml 111 114 103 106 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(B)</bold>
###xml 639 642 625 628 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(C)</bold>
B and C) Ligand-dependent regulation of PPARgamma target genes in IDCs from subjects with PPARgamma mutations. (B)Induction of the aP2 gene by rosiglitazone, measured by qPCR, is markedly impaired in IDCs derived from subjects with the C114R, C131Y, FS315X, and R357X mutations, compared to responses in cells from normal (WT), severely insulin resistant (IR) subjects without mutations in PPARgamma and cells with the FSX, haploinsufficient, mutation. Results represent the mean +/- SEM of more than three independent experiments in triplicate, except for cells with the FS315X mutation where a single representative experiment is shown. (C) Relative expression of several PPARgamma target genes (5 downregulated and 5 upregulated) in WT and mutation-containing (FSX, C114R, R357X) IDCs, measured by qPCR using TLDA. Red indicates higher, and blue lower, levels of gene expression relative to rosiglitazone-treated (1000 nM) WT cells, whose responses are uniformly designated yellow. Fold changes in expression of each gene in rosiglitazone (RSG) versus vehicle (DMSO) treated WT cells are also listed.
###end p 132
###begin p 133
###xml 0 8 0 8 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D and E)</bold>
###xml 58 61 54 57 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(D)</bold>
###xml 378 381 370 373 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(E)</bold>
###xml 138 145 <span type="species:ncbi:9606">patient</span>
D and E) The R357X PPARgamma mutant is expressed in IDCs. (D) PPARgamma cDNA flanking the R357 codon was amplified by RT-PCR in IDCs from patient S5 and a control subject. Cac81 enzyme digestion of PCR products derived from the WT allele yields two fragments (161 and 74 bp), whereas abolition of this restriction site in the R357X mutant allele yields a larger 235 bp product. (E) Whole-cell lysates of WT and R357X mutant IDCs and 293EBNA cells transfected with R357X mutant were immunoprecipitated and Western blotted. The positions of WT PPARgamma (open arrow), R357X (solid arrow), and nonspecific bands (solid arrowheads) are indicated.
###end p 133
###begin p 134
###xml 70 75 <span type="species:ncbi:9606">human</span>
Adenoviral-mediated expression of the C114R PPARgamma mutant inhibits human preadipocyte differentiation
###end p 134
###begin p 135
###xml 0 4 <span type="species:ncbi:8284">Chub</span>
###xml 8 13 <span type="species:ncbi:9606">human</span>
Chub-S7 human preadipocyte cells were infected with comparable efficiency using recombinant adenoviruses expressing GFP, GFP-WT, or GFP-C114R mutant PPARgamma and differentiated in the presence of rosiglitazone (100nM).
###end p 135
###begin p 136
###xml 0 2 0 2 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A)</bold>
###xml 24 28 <span type="species:ncbi:8284">Chub</span>
A) Fully differentiated Chub-S7 cells fixed and stained with oil red O.
###end p 136
###begin p 137
###xml 0 2 0 2 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B)</bold>
B) aP2 expression quantitated by real-time qPCR at days 0, 3, 5, and 7 postdifferentiation with results representing the mean +/- SEM of at least three independent experiments in triplicate.
###end p 137
###begin p 138
###xml 0 2 0 2 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C)</bold>
###xml 23 27 <span type="species:ncbi:8284">Chub</span>
C) Western blotting of Chub-S7 cells at day 4 posttransduction with recombinant adenoviruses confirming comparable levels of total receptor expression. Nondifferentiated, (day 0) nontransduced, cell extracts (ND) are shown for comparison. The positions of PPARgamma (open arrow) and non specific band (solid arrowhead) are indicated.
###end p 138
###begin p 139
Clinical, biochemical, and body composition details
###end p 139
###begin p 140
###xml 279 297 279 297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R12">Black et al., 1983</xref>
###xml 710 717 <span type="species:ncbi:9606">patient</span>
BMI, body mass index; BP, blood pressure; T2DM, type 2 diabetes mellitus; IGT, impaired glucose tolerance; PCOS, polycystic ovarian syndrome; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; FI, fasting insulin; Predicted total body fat was calculated as follows (Black et al., 1983): males % fat = (1.281 x BMI) - 10.13: females % fat = (1.48 x BMI) - 7.00; measured total and depot-specific body fat were determined using dual-energy X-ray absorptiometry, with corresponding z scores for total body fat shown as superscript; Hepatic steatosis was diagnosed according to standard radiological criteria; F, female; healthy adult values where available are shown in parentheses; asterisk denotes patient studied on treatment; N/A, not applicable; nd, not determined.
###end p 140

